Blog
RSS FeedPosted by Michael Wonder on 08 Sep 2021
NICE draft guidance recommends apalutamide for treating prostate cancer
8 September 2021 - NICE has today published final draft guidance which now recommends apalutamide (Erleada; Janssen) plus androgen deprivation therapy ...
Posted by Michael Wonder on 01 Sep 2021
NICE approves ground-breaking cholesterol lowering drug inclisiran
1 September 2021 - NICE has today issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by ...
Posted by Michael Wonder on 01 Sep 2021
World first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio (inclisiran)
1 September 2021 - Agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management ...
Posted by Michael Wonder on 20 Aug 2021
NICE draft guidance extends recommendation for sapropterin to pregnant women and people aged up to 22 years with rare inherited metabolic condition phenylketonuria
20 August 2021 - NICE has today issued final draft guidance which now recommends sapropterin (Kuvan; BioMarin) as an option for ...
Posted by Michael Wonder on 19 Aug 2021
NICE recommends first treatment for rare blood disorder
19 August 2021 - People with a rare blood disorder have access to a new treatment following draft guidance from NICE. ...
Posted by Michael Wonder on 18 Aug 2021
NICE publishes final guidance on the use of a topical gel for patients with a rare cancer
18 August 2021 - Chlormethine gel for is used for the treatment of patients with mycosis fungoides type cutaneous T-cell lymphoma. ...
Posted by Michael Wonder on 18 Aug 2021
Abiraterone acetate for treating newly diagnosed high-risk hormone sensitive metastatic prostate cancer
18 August 2021 - NICE has published final guidance on the use of Zytiga in newly diagnosed patients following an ...
Posted by Michael Wonder on 12 Aug 2021
NICE draft guidance recommends abemaciclib for advanced breast cancer
12 August 2021 - NICE has today published draft guidance which recommends a twice daily pill abemaciclib (Verzenios; Eli Lilly) as ...
Posted by Michael Wonder on 22 Jul 2021
Patients with rare bile duct cancer set to benefit from life extending treatment
22 July 2021 - Some people who have a rare form of bile duct cancer are set to benefit from life-extending ...
Posted by Michael Wonder on 16 Jul 2021
Ledaga recommended by NICE for rare type of lymphoma
16 July 2021 - NICE has recommended Recordati Rare Diseases and Helsinn Healthcare’s Ledaga for a type of lymphoma that ...
Posted by Michael Wonder on 11 Jul 2021
NICE publishes draft guidance on the use of Libmeldy
9 July 2021 - OTL-200 (Libmeldy) is a gene therapy medicinal product that expresses the human ARSA gene. ...
Posted by Michael Wonder on 07 Jul 2021
Enzalutamide for men with hormone sensitive metastatic prostate cancer
7 July 2021 - NICE publishes final guidance on a new indication for Xtandi. ...
Posted by Michael Wonder on 07 Jul 2021
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
7 July 2021 - Final guidance published after appeal. ...
Posted by Michael Wonder on 21 Jun 2021
Novartis’ Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis
18 June 2021 - Novartis’ Cosentyx has been recommended by NICE for the treatment of adults with non-radiographic axial spondyloarthritis. ...
Posted by Michael Wonder on 10 Jun 2021
Astellas’ Xtandi bags NICE approval in prostate cancer
10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate ...